Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib

@article{Deininger2003SpecificTT,
  title={Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib},
  author={Michael W N Deininger and Brian J. Druker},
  journal={Pharmacological Reviews},
  year={2003},
  volume={55},
  pages={401 - 423}
}
Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete… 
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
TLDR
The rationale for strategies to avoid and overcome imatinib resistance in the management of CML patients is established and rates of resistance and relapse correlate with the stage of disease and with the monitoring parameters – hematologic, cytogenetic and molecular response.
Optimizing treatment of chronic myeloid leukemia: a rational approach.
TLDR
A randomized, phase III comparison of Imatinib with interferon-alfa plus cytarabine as initial treatment for newly diagnosed chronic-phase CML, which demonstrated significantly higher rates of disease response with less toxicity, better quality of life, and a significantly longer progression-free survival time, provided the most persuasive data supporting a major role for imatinib.
Case study of primary imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia
TLDR
This is a case study of multiple point mutations conferring primary imatinib resistance in one patient at the same time, and the allele-specific oligonucleotide-polymerase chain reaction assay is very effective in detecting mutations related to imatinIB resistance.
Imatinib spells BAD news for Bcr/abl-positive leukemias
  • S. Kaufmann
  • Biology, Medicine
    Proceedings of the National Academy of Sciences
  • 2006
TLDR
New insight is provided into the cytotoxic action of imatinib and another mechanism of resistance and a means for overcoming it are potentially identified.
Imatinib in Chronic Myeloid Leukemia: an Overview
  • T. Sacha
  • Medicine
    Mediterranean journal of hematology and infectious diseases
  • 2014
TLDR
Results from this study show the outstanding effectiveness of imatinib and its superiority with respect to the rates of complete hematological response (CHR), major and complete cytogenetic response (MCyR, CCyR).
Leukemia Stem Cells in Chronic Myeloid Leukemia.
TLDR
A significant progress has been made in studying the biology of LSCs in both animal models and human patients at cellular and molecular levels, providing a basis for designing and testing potential molecular targets for eradicating L SCs in CML.
New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?
TLDR
Current and emerging paradigms for using Abl kinase inhibitors to achieve maximal disease control and strategies to eradicate disease by targeting leukemic stem cells are reviewed.
Localisation, activity and targeting of Bcr-Abl in chronic myeloid leukaemia
TLDR
It was demonstrated that p-CrkL was not a reliable indicator of Bcr-Abl kinase activity within 24 hours of IM treatment in vitro and indicated that the early responses to IM and dasatinib were different, and a farnesyltransferase inhibitor (FTI) BMS-214662 preferentially induces apoptosis in CML cells.
Mechanisms of Disease Persistence in Chronic Myelogenous Leukemia (CML)
TLDR
Using in vitro culture of primary CML progenitor cells, both quiescent and cycling cells capable of surviving in the presence of imatinib are identified, suggesting a Bcr-Abl independent mechanism of survival.
Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations
TLDR
Principals previously used to develop combination chemotherapy to avoid the development of multidrug resistance in leukemias and lymphomas may prove useful in the approach to the next generation of targeted molecular therapeutics for CML.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 215 REFERENCES
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
TLDR
Although the heterogeneous development of imatinib resistance is challenging, the fact that BCR-ABL is active in many resistant patients suggests that the chimeric oncoprotein remains a good therapeutic target.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
TLDR
Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase, and a daily dose of 600 mg is more effective than 400 mg, with similar toxicity.
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate
TLDR
The presence of clonal abnormalities in Ph-negative cells of imatinib-treated CML patients with MCR and CHR highlights the importance of routine metaphase cytogenetic testing and long-term follow-up of all imatinIB-treated patients.
Effects of imatinib on bone marrow engraftment in syngeneic mice
TLDR
It is found that Imatinib has no significant influence on hematopoietic recovery in lethally irradiated mice in vivo, suggesting that continued administration of imatinib in the course of BMT or SCT may be a feasible therapeutic regimen.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
TLDR
It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
TLDR
Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph(+) acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid.
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
TLDR
The results are consistent with the notion that targeted therapy of CML with Imatinib favors the manifestation of Ph- clonal disorders in some patients and indicate that patients on imatinib should be followed with conventional cytogenetics, even after induction of CCR.
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
TLDR
Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases associated with activation of PDGFRB and all responses were durable at 9 to 12 months of follow-up.
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
TLDR
It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested.
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
TLDR
The data indicate that PD180970 is active against several Bcr-Abl mutations that are resistant to imatinib and support the notion that developing additional Abl kinase inhibitors would be useful as a treatment strategy for chronic myelogenous leukemia.
...
1
2
3
4
5
...